Trial TCTR20211027002
Publication Nantanee R, Vaccine, 2022
Primary outcome on the report: 1) GMR of sVNT against variants of concern, and 2) anti-S-RBD IgG, comparing the half- with the standard-dose groups at day 14 and 90 after booster

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.